Thymosin Alpha-1

Thymosin Alpha-1 (Ta1) is a 28-amino acid peptide naturally produced by the thymus gland. The thymus is the master organ of immune function, and its progressive involution (shrinkage) with age is a primary driver of age-related immune decline (immunosenescence).

As a pharmaceutical product (Zadaxin), Thymosin Alpha-1 is approved in over 35 countries for conditions including hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. It has been used clinically in over 1 million patients worldwide.

Ta1 works by enhancing the differentiation and function of T-cells, activating dendritic cells for improved antigen presentation, and modulating cytokine production to balance immune responses. Importantly, it acts as an immune modulator rather than a simple stimulant - it upregulates suppressed immunity while dampening overactive inflammatory responses.

During the COVID-19 pandemic, several clinical studies investigated Ta1 as an adjunct therapy, with results showing improved lymphocyte counts and reduced mortality in critically ill patients.